MTNB — Matinas BioPharma Holdings Share News
0.000.00%
Last trade - 00:00Brief: Matinas Biopharma Initiates Dosing In Phase 1 Study Of Potential First Oral Aminoglycoside Antibiotic Drug Mat2501
Brief: Matinas Reports Positive Data In Ongoing EnACT Trial of MAT2203 For Treatment Of Cryptococcal Meningitis
Matinas rises on positive data from first two cohorts in meningitis drug study
Brief: Matinas Biopharma Announces Issuance Of U.S. Patent Protecting Mat2203 To Treat Or Prevent Cryptococcus Infections
Brief: Matinas BioPharma Reports Second Quarter 2021 Financial Results And Operational Highlights
Brief: Matinas Biopharma Reports Q1 Loss Per Share Of $0.03
U.S. RESEARCH ROUNDUP-Acuity Brands, Viacomcbs, Yelp
Brief: Matinas BioPharma Reports Q4 Loss Per Share Of $0.03
Brief: Matinas BioPharma Announces Topline Results From ENHANCE-IT Study of LYPDISO Against Vascepa
U.S. STOCKS ON THE MOVE-Cyclo Therapeutics, Atomera Inc, Conagra Brands Inc
U.S. RESEARCH ROUNDUP-Brookfield Property Partners LP, Calithera Biosciences, Cree
Brief: Matinas Biopharma Says MAT9001 Contract Manufacturer Suffered Explosion At Asia Manufacturing Facilities
Matinas up on plans to develop oral formulations of COVID-19 drug remdesivir
Brief: Matinas Biopharma Announces Collaboration With National Institute Of Allergy And Infectious Diseases To Evaluate Oral Formulations Of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
Brief: Matinas Biopharma Holdings Inc Awarded Up To $3.75 Million From Cystic Fibrosis Foundation
Brief: Matinas Biopharma Reports Third Quarter 2020 Financial Results And Operational Highlights
Brief: Matinas Biopharma Announces Unanimous Dsmb Approval To Progress Into Second Cohort Of Patients In The Enact Study Of Mat2203 For The Treatment Of Cryptococcal Meningitis
Brief: Matinas Biopharma Holdings Announces Positive End Of Phase 2 Meeting With FDA For MAT9001 In Severe Hypertriglyceridemia
Brief: Matinas Biopharma Completes Enrollment Of ENHANCE-IT Study Of MAT9001 Against Vascepa